

Satsuma Pharmaceuticals, Inc.

## Satsuma Pharmaceuticals to participate in the following November Virtual Investor Conferences

- Credit Suisse - 29th Annual Healthcare Conference - November 9th -12th

- Stifel 2020 Virtual Healthcare Conference - November 16th -18th

South San Francisco, CA, November 2, 2020— [Satsuma Pharmaceuticals, Inc.](#) (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will participate in the following conferences in the month of November. Please see additional details below:

### **Credit Suisse 29<sup>th</sup> Annual Healthcare Conference**

Dates: Monday – Thursday, November 9<sup>th</sup>-12<sup>th</sup> 2020

Format: *One-on-One meetings with Satsuma Management*

Location: Virtual Meetings

### **Stifel 2020 Virtual Healthcare Conference**

Date: Monday – Wednesday, November 16<sup>th</sup>-18<sup>th</sup> 2020

Format: *One-on-One meetings with Satsuma Management*

Location: Virtual Meetings

### **About Satsuma Pharmaceuticals and STS101**

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101. STS101 is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. In developing STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, simple-to-use, non-injectable DHE product that can be rapidly self-administered in a matter of seconds.

Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit [www.satsumarx.com](http://www.satsumarx.com).

### **INVESTOR AND CORPORATE CONTACTS:**

Corey Davis, PhD  
LifeSci Advisors, LLC  
[cdavis@lifesciadvisors.com](mailto:cdavis@lifesciadvisors.com)

Tom O'Neil, Chief Financial Officer  
Satsuma Pharmaceuticals, Inc.  
[tom@satsumarx.com](mailto:tom@satsumarx.com)

---

<https://investors.satsumarx.com/2020-11-02-Satsuma-Pharmaceuticals-to-participate-in-the-following-November-Virtual-Investor-Conferences>